About this trial
The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis
women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)
Disqualifiers
patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old.
patients on systemic corticosteroids with corticosteroid therapy > 10 mg prednisone equivalent
pregnant woman
Trial design
Single group
Treatments tested in this trial
measurement of salt intake
Other interventionmeasurement of salt intake without intervention
Treatment groups
Trial outcomes
Primary outcomes
sodium intake
average sodium concentration in urine for the week
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Centre Hospitalier Universitaire de Besancon
Lead sponsor
French Society of Rheumatology
Collaborator